Does the PSA blood test actually save lives?
Yes. A new Cochrane review of six trials including nearly 800,000 men found that PSA screening reduces death from prostate cancer by about 2 fewer deaths per 1,000 men screened. That finding reverses an earlier 2013 Cochrane review which had concluded there was no clear mortality benefit.
The prostate-specific antigen test, or PSA, is a simple blood test that measures a protein made by the prostate gland. Higher levels can be a sign of prostate cancer, but they can also rise for other reasons. For years, doctors have argued about whether routine PSA screening helps more than it harms. This new review pulls together the best evidence we have and shifts the balance toward benefit, while keeping a careful eye on the trade-offs.
What the Data Show
The reviewers pooled six randomized trials with a combined 789,086 men aged 45 to 80 from Europe and North America. The three largest studies, the UK CAP trial, the US PLCO trial, and the European ERSPC trial, made up 85% of all participants. Follow-up times ranged from about 3 years to 23 years.
The most reliable estimate, drawn from the highest-quality data, showed that screening cut the rate of prostate-cancer-specific death by 13%. Translated into real numbers, that means about 2 fewer prostate cancer deaths for every 1,000 men screened, against a baseline of 16 deaths per 1,000. Screening also appeared to reduce death from any cause slightly, with about 5 fewer total deaths per 1,000 men, though the confidence interval here was wide and the certainty of this effect was low.
Screening also led to more cancers being found. PSA testing increased overall prostate cancer diagnoses by 30% and early-stage (localized) diagnoses by 53%. On the other side of the ledger, it reduced metastatic prostate cancer diagnoses by about 35% and modestly lowered advanced-stage cases.
Dr. Kumar’s Take
I find this update important, and a bit overdue. The 2013 Cochrane review concluded there was no clear survival benefit from PSA screening, and that finding shaped how many primary care doctors talk to patients about this test. Now, with longer follow-up and two new large trials, the picture has shifted. Screening looks like it really does prevent some prostate cancer deaths.
But I do not read this as a green light for every man to start getting PSA tests. The benefit is real but modest, and the cost is meaningful. To prevent one or two deaths, you have to diagnose around 36 extra men with prostate cancer. Many of those men will undergo biopsies, surgery, or radiation for cancers that never would have hurt them. That is the heart of the overdiagnosis problem, and this review does not make it go away.
How strong is the evidence?
The certainty of evidence varied by outcome. The reviewers used the GRADE system, which rates findings from very low to high certainty. The drop in prostate cancer deaths was rated moderate certainty, which is reasonably strong. The reduction in overall mortality was rated low certainty, mostly because the confidence interval included the possibility of no effect at all.
One important note: the headline mortality result comes from a sensitivity analysis using the ERSPC trial, the European study judged to have the lowest risk of bias. When the reviewers pooled all eligible trials together, the picture was less clear. That is partly because the US PLCO trial had high rates of PSA testing in its control group, which made it harder to detect a true difference. Differences in trial design, screening frequency, and follow-up also added uncertainty.
Safety, Limits, and Caveats
The review found little evidence of difference in serious adverse events tied directly to screening itself, measured as deaths from biopsies or cancer treatment. Quality of life scores between screened and unscreened men were nearly identical.
But the authors flag a real gap: they did not have good data on the everyday harms of overtreatment, like urinary incontinence, erectile dysfunction, and bowel problems from surgery or radiation. These complications affect many men diagnosed through screening, including those whose cancers would have never become dangerous. That missing piece matters because it is exactly the cost most men weigh when deciding whether to test.
The review also looked at a newer approach combining PSA, a kallikrein panel, and MRI scans. Early results suggest this method finds more cancers but its effect on death is still unknown.
Practical Takeaways
- Talk with your doctor about PSA testing starting around age 50, or earlier if you are Black or have a father or brother with prostate cancer, since these groups face higher risk.
- Weigh the trade-off honestly: for every 1 or 2 deaths prevented, roughly 36 additional men get a prostate cancer diagnosis, and many of those cancers may never have caused harm.
- If your PSA comes back high, ask whether MRI before biopsy is an option, since this approach can reduce unnecessary biopsies and may catch significant cancers more reliably.
- Remember that finding cancer is not the same as needing treatment. Active surveillance, which means careful monitoring instead of immediate surgery, is a legitimate option for many low-risk prostate cancers.
Related Studies and Research
- is testosterone safe for men after prostate cancer surgery?
- pre-sleep protein consumption: systematic review of muscle-related outcomes
- real-world brexanolone outcomes: 12-month follow-up shows sustained benefits
- ect reduces suicidality and mortality in refractory depression
FAQs
At what age should men start getting PSA tests?
Most guidelines suggest a shared decision-making conversation between ages 50 and 55 for average-risk men, and earlier (around 40 to 45) for men at higher risk. Higher-risk groups include Black men and men with a father, brother, or son diagnosed with prostate cancer. The trials in this Cochrane review enrolled men from age 45 onward, so the evidence base does not strongly support routine screening in younger men. Talk to your doctor about your specific risk profile rather than relying on a one-size-fits-all rule.
What counts as a “high” PSA result and does it always mean cancer?
There is no single cutoff that universally signals cancer, but values above 4 ng/mL have traditionally prompted further evaluation. A high PSA can come from prostate cancer, but it can also rise from a benign enlarged prostate, infection, recent ejaculation, vigorous cycling, or even a urinary tract infection. Because PSA is not specific to cancer, follow-up testing such as a repeat PSA, an MRI scan, or a biopsy is typically needed before any diagnosis is made. This is one reason the test is controversial, since many men with elevated PSA do not have clinically significant cancer.
What is overdiagnosis and why does it matter for prostate cancer?
Overdiagnosis means detecting a cancer that would never have caused symptoms or shortened a person’s life. Prostate cancer often grows slowly, especially in older men, and many men die with prostate cancer rather than from it. Screening can pick up these slow-growing cancers along with the dangerous ones, and once a man has a cancer diagnosis, the pressure to treat is strong. Treatment carries its own risks including incontinence, sexual dysfunction, and bowel problems, which is why the trade-off between catching dangerous cancers and overtreating harmless ones is so central to this conversation.
Bottom Line
After more than a decade of uncertainty, the updated Cochrane review tips the balance: PSA screening likely does save some lives from prostate cancer, preventing roughly 2 deaths per 1,000 men screened over long follow-up. But the benefit is modest and comes paired with substantial overdiagnosis, meaning many men receive cancer diagnoses and treatments they may never have needed. This is not a reason to skip the conversation with your doctor, and it is not a reason to demand the test reflexively either. It is a reason to make an informed, individualized decision based on your age, risk, and values.
